<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657460</url>
  </required_header>
  <id_info>
    <org_study_id>v1.4</org_study_id>
    <nct_id>NCT02657460</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion</brief_title>
  <official_title>Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to investigate the anticancer effect and the related immunological mechanism of&#xD;
      MTX-ATMPs in the treatment of malignant pleural effusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pleural effusion(MPE) as a common complication of advanced lung cancer is lack of&#xD;
      efficient treatments. The investigators have successfully produced tumor cell-derived&#xD;
      microparticles packaging chemotherapy drugs and confirmed that this new integrative targeted&#xD;
      biochemotherapy treatment could effectively restrain tumor growth at cellular and animal&#xD;
      levels.This new method could control tumor growth in vivo effectively and induced pleural&#xD;
      adhesion in the early clinical study. So the investigators attempt to explore the anticancer&#xD;
      effect and related immune regulation mechanism of methotrexate-autologous tumor derived&#xD;
      microparticles (MTX-ATMPs) in MPE treatment. The tumor cells in the malignant pleural&#xD;
      effusion are prepared by screening, then MTX-ATMPs are made. Participants enrolled are&#xD;
      randomly assigned to experimental and control group, each of them is injected with the&#xD;
      prepared drug once in two days until the malignant pleural effusion are disappeared or the&#xD;
      treatment cycle has been six times. During or after the whole treatment, reactions to each&#xD;
      treatment of the participants are carefully followed up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pleural effusions volume</measure>
    <time_frame>four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rivalta Test of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total protein level of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total karyocytes count of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactic dehydrogenase level of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adenosine deaminase level of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the cytology test of pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky index</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival time</measure>
    <time_frame>six month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carcino embryonie antigen level in microgramme/L in serum</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYFRA21-1 level in ng/mL in serum</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuron specific annuals level in microgramme/L in serum</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>squamous cell carcinoma antigen level in ng/mL in serum</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carcino embryonie antigen level in microgramme/L in pleural effusions</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>MTX-ATMPs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methotrexate-autologous tumor derived microparticles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Cisplatin is a traditional treatment for lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tumor derived microparticles</intervention_name>
    <description>The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.</description>
    <arm_group_label>MTX-ATMPs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin is a traditional drug for lung cancer</description>
    <arm_group_label>cisplatin</arm_group_label>
    <other_name>cisplatinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The diagnosis of lung cancer and malignant pleural effusion was confirmed by pathology&#xD;
             and / or pleural fluid cytology;&#xD;
&#xD;
          2. The routine surgery or systemic radio/chemotherapy was ineffective, the MPE relapsed,&#xD;
             or routine treatment therapy was given up by self-causes;&#xD;
&#xD;
          3. stable vital sign with KPS(Karnofsky Performance Status) index more than 60;&#xD;
&#xD;
          4. 18-70 years old;&#xD;
&#xD;
          5. normal haematopoietic function of bone marrow, no hemorrhagic tendency, blood routine&#xD;
             test: HGB&gt;=100g/L, WBC&gt;4.0*10^9/L, PLT&gt;80*10^9/L, serum ALT, AST within 2 times upper&#xD;
             limit of normal, BUN within 1.5 time upper limit of normal, creatinine within normal&#xD;
             range, normal EKG;&#xD;
&#xD;
          6. agreed to participate in the study and sign an informed consent;&#xD;
&#xD;
          7. without other severe comorbidities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. lactating or pregnant patients;&#xD;
&#xD;
          2. allergy to multiple drugs;&#xD;
&#xD;
          3. with other severe comorbidities or psychological diseases;&#xD;
&#xD;
          4. severe infection;&#xD;
&#xD;
          5. participation in other clinical trials within the recent three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Jin, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Wu, Master</last_name>
    <phone>086-13476080943</phone>
    <email>wufengxiehe@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Jin, doctor</last_name>
      <phone>+86 13554361146</phone>
      <email>whuhjy@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>February 24, 2019</last_update_submitted>
  <last_update_submitted_qc>February 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Yang Jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>microparticle</keyword>
  <keyword>malignant pleural effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share IPD now</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

